Eli Lilly and Company: Colitis, Ulcerative trials
The registry lists 16 Colitis, Ulcerative studies with Eli Lilly and Company as lead sponsor. 5 are open to participants now and 7 have results posted.
Phase 2 8Phase 3 8(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's DiseaseRecruitingNCT07483073Phase 2
- LY4268989 in Adults With Moderately to Severely Active Ulcerative ColitisRecruitingNCT07415044Phase 2
- LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:RecruitingNCT07186101Phase 2
- Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b StudyRecruitingNCT06937086Phase 3
- A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)RecruitingNCT04844606Phase 3
- A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative ColitisCompletedNCT05767021Phase 3Results posted
- A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UCCompletedNCT05611671Phase 2Results posted
- A Phase 2a Open-Label Study to Evaluate the Efficacy and Safety of MORF-057 in Adults With UCCompletedNCT05291689Phase 2Results posted
- A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC)CompletedNCT04004611Phase 2Results posted
- A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative ColitisCompletedNCT03524092Phase 3Results posted
- An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)CompletedNCT03518086Phase 3Results posted
- A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Ulcerative ColitisCompletedNCT02589665Phase 2Results posted
- A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative ColitisActive, not recruitingNCT06598943Phase 2
- A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative ColitisCompletedNCT05784246Phase 3
- A Study of Mirikizumab (LY3074828) in Participants With Ulcerative ColitisWithdrawnNCT04469062Phase 3
- A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)Active, not recruitingNCT03519945Phase 3